Nameton 500: Each film-coated tablet contains Nabumetone USP 500 mg.
Nameton 750: Each film-coated tablet contains Nabumetone USP 750 mg.
Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in pharmacologic studies. The ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect. The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis.
Nabumetone is indicated for acute and chronic treatment of signs and symptoms of Osteoarthritis and Rheumatoid arthritis.
Osteoarthritis and Rheumatoid Arthritis: The recommended starting dose is 1,000 mg taken as a single dose with or without food. To obtain more symptomatic relief patients may take dose from 1,500 mg to 2,000 mg per day. Nabumetone can be given in either a single or twice-daily dose. For chronic use 1000 mg daily dose should be taken.
Renal Insufficiency: Caution should be taken in prescribing Nabumetone to patients with moderate to severe renal insufficiency. The maximum starting doses of Nabumetone in patients with moderate or severe renal insufficiency should not exceed 750 mg or 500 mg, respectively once daily. Following careful monitoring of renal function in patients with moderate to severe renal insufficiency, daily doses may be increased to a maximum of 1500 mg and 1000 mg respectively.
Hepatic Impairment: Nabumetone should be used with caution in patients with severe hepatic impairment.
Caution should be exercised when administering Nabumetone with warfarin. Because of its affinity for protein active metabolites 6-MNA may displace other protein bound drugs from their binding site.
Overdose:
Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and anaphylactic reactions may occur.
Pregnancy: Pregnancy category C. There are no adequate, well tolerated studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Use of nabumetone during third trimester of pregnancy is not recommended.
Lactation: Nabumetone is not recommended for use in nursing mothers. It is not known whether Nabumetone or its metabolites are excreted in human milk.
Safety and effectiveness in pediatric patients have not been established.
As with any NSAIDs, caution should be exercised in treating the elderly.
As a class, NSAIDs have been associated with renal papillary necrosis and other abnormal renal pathology during long term administration to animals. A second form of renal toxicity often associated with NSAIDs is seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal perfusion. In these patients, administration of an NSAID results in a dose-dependent decrease in prostaglandin synthesis and secondarily, in a reduction of renal blood flow, which may precipitate over renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and the elderly. Discontinuation of NSAID therapy is typically followed by recovery to the pretreatment state.
Store below 30°C temperature & dry place, protected from light. Keep all medicines out of reach of children.